An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma
We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m 2 , day 1), ifosfamide (1500 mg/m 2 on days 3–7), etoposide (150 mg/m 2 , days 3–5), cytarabine (100 mg/m 2 , days 3–5) and dexamethasone (40 mg/body, days 3–5) (R-IVAD) for relapsed or refractory aggr...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2011-07, Vol.94 (1), p.90-96 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 1 |
| container_start_page | 90 |
| container_title | International journal of hematology |
| container_volume | 94 |
| creator | Miura, Katsuhiro Takei, Kazuhiro Kobayashi, Sumiko Kiso, Satomi Hirabayashi, Yukio Hojo, Atsuko Kodaira, Hitomi Yagi, Mai Kurita, Daisuke Kobayashi, Yujin Tanaka, Toshitake Iriyama, Noriyoshi Hatta, Yoshihiro Kura, Yoshimasa Yamazaki, Tetsuo Sawada, Umihiko Takeuchi, Jin |
| description | We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m
2
, day 1), ifosfamide (1500 mg/m
2
on days 3–7), etoposide (150 mg/m
2
, days 3–5), cytarabine (100 mg/m
2
, days 3–5) and dexamethasone (40 mg/body, days 3–5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma. In this study, a total of 32 patients with a median age of 64 years (range 38–79) who received an average of 2.6 cycles of R-IVAD from 2001 to 2009 in our institution were retrospectively analyzed. R-IVAD was given every 3 weeks up to a total of three courses with support by granulocyte colony stimulating factor. The overall response rate was 72%, with 56% complete response. On a median follow-up of 16 months (range 2–99), estimated 2-year overall survival (OS) and event-free survival were 55% and 36%, respectively. Of these patients, 10 successfully proceeded to consolidating high-dose chemotherapy followed by autologous stem cell transplantation, accounting for 90% of the 2-year OS. No treatment-related mortality was observed during the investigation. We, therefore, conclude that R-IVAD regimen is a safe and efficacious alternative for patients with relapsed or refractory aggressive B-cell lymphoma. |
| doi_str_mv | 10.1007/s12185-011-0884-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_875029990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2392485081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-313c56b2a67bf7f23f1dc6a3f7d39bfd026954435eb6d72a9266b669b93cf8153</originalsourceid><addsrcrecordid>eNp1kduKFDEQhoMo7rj6AN5IEAQFozl0ks7luJ4WFgRRb5vqdDKTpU-bpNeZx_INzTije-VVKtRXVX_Vj9BTRt8wSvXbxDirJaGMEVrXFdndQytWK0mE1tV9tKKGSyI1o2foUUrXlDJNK_0QnXGmjFSUrtCv9Yid987mcOtwgv4WNg7n6CAPbsx4SWHc4OCn5GEInXuNXZ7mKf0J7T5DhDaMJe7cDgaXt5CmwxfGDseQl10YoMUvv5LLH-v3r7CfIp4hh9I64Z8hb3F0PczJdbhkovMRbJ7iHsNmE11KB1HviHV9j_v9MG-nAR6jBx765J6c3nP0_eOHbxefydWXT5cX6ytiKykyEUxYqVoOSrdeey4866wC4XUnTOs7yssJqkpI16pOczBcqVYp0xphfc2kOEfPj33nON0sLuXmelriWEY2tZaUG2NogdgRsnFKqehv5lg2jvuG0ebgUXP0qCkeNQePml2peXZqvLSD6_5V_DWlAC9OACQLfbnJaEO64yopqRKmcPzIpZIaNy7eKfz_9N-waqzK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>875029990</pqid></control><display><type>article</type><title>An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Miura, Katsuhiro ; Takei, Kazuhiro ; Kobayashi, Sumiko ; Kiso, Satomi ; Hirabayashi, Yukio ; Hojo, Atsuko ; Kodaira, Hitomi ; Yagi, Mai ; Kurita, Daisuke ; Kobayashi, Yujin ; Tanaka, Toshitake ; Iriyama, Noriyoshi ; Hatta, Yoshihiro ; Kura, Yoshimasa ; Yamazaki, Tetsuo ; Sawada, Umihiko ; Takeuchi, Jin</creator><creatorcontrib>Miura, Katsuhiro ; Takei, Kazuhiro ; Kobayashi, Sumiko ; Kiso, Satomi ; Hirabayashi, Yukio ; Hojo, Atsuko ; Kodaira, Hitomi ; Yagi, Mai ; Kurita, Daisuke ; Kobayashi, Yujin ; Tanaka, Toshitake ; Iriyama, Noriyoshi ; Hatta, Yoshihiro ; Kura, Yoshimasa ; Yamazaki, Tetsuo ; Sawada, Umihiko ; Takeuchi, Jin</creatorcontrib><description>We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m
2
, day 1), ifosfamide (1500 mg/m
2
on days 3–7), etoposide (150 mg/m
2
, days 3–5), cytarabine (100 mg/m
2
, days 3–5) and dexamethasone (40 mg/body, days 3–5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma. In this study, a total of 32 patients with a median age of 64 years (range 38–79) who received an average of 2.6 cycles of R-IVAD from 2001 to 2009 in our institution were retrospectively analyzed. R-IVAD was given every 3 weeks up to a total of three courses with support by granulocyte colony stimulating factor. The overall response rate was 72%, with 56% complete response. On a median follow-up of 16 months (range 2–99), estimated 2-year overall survival (OS) and event-free survival were 55% and 36%, respectively. Of these patients, 10 successfully proceeded to consolidating high-dose chemotherapy followed by autologous stem cell transplantation, accounting for 90% of the 2-year OS. No treatment-related mortality was observed during the investigation. We, therefore, conclude that R-IVAD regimen is a safe and efficacious alternative for patients with relapsed or refractory aggressive B-cell lymphoma.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-011-0884-x</identifier><identifier>PMID: 21695600</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject><![CDATA[Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - toxicity ; Biological and medical sciences ; Cytarabine - administration & dosage ; Dexamethasone - administration & dosage ; Etoposide - administration & dosage ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Ifosfamide - administration & dosage ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, B-Cell - complications ; Lymphoma, B-Cell - drug therapy ; Lymphoma, B-Cell - mortality ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Retrospective Studies ; Rituximab ; Salvage Therapy - adverse effects ; Salvage Therapy - methods ; Survival Analysis ; Treatment Outcome]]></subject><ispartof>International journal of hematology, 2011-07, Vol.94 (1), p.90-96</ispartof><rights>The Japanese Society of Hematology 2011</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-313c56b2a67bf7f23f1dc6a3f7d39bfd026954435eb6d72a9266b669b93cf8153</citedby><cites>FETCH-LOGICAL-c453t-313c56b2a67bf7f23f1dc6a3f7d39bfd026954435eb6d72a9266b669b93cf8153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-011-0884-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-011-0884-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24550639$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21695600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miura, Katsuhiro</creatorcontrib><creatorcontrib>Takei, Kazuhiro</creatorcontrib><creatorcontrib>Kobayashi, Sumiko</creatorcontrib><creatorcontrib>Kiso, Satomi</creatorcontrib><creatorcontrib>Hirabayashi, Yukio</creatorcontrib><creatorcontrib>Hojo, Atsuko</creatorcontrib><creatorcontrib>Kodaira, Hitomi</creatorcontrib><creatorcontrib>Yagi, Mai</creatorcontrib><creatorcontrib>Kurita, Daisuke</creatorcontrib><creatorcontrib>Kobayashi, Yujin</creatorcontrib><creatorcontrib>Tanaka, Toshitake</creatorcontrib><creatorcontrib>Iriyama, Noriyoshi</creatorcontrib><creatorcontrib>Hatta, Yoshihiro</creatorcontrib><creatorcontrib>Kura, Yoshimasa</creatorcontrib><creatorcontrib>Yamazaki, Tetsuo</creatorcontrib><creatorcontrib>Sawada, Umihiko</creatorcontrib><creatorcontrib>Takeuchi, Jin</creatorcontrib><title>An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m
2
, day 1), ifosfamide (1500 mg/m
2
on days 3–7), etoposide (150 mg/m
2
, days 3–5), cytarabine (100 mg/m
2
, days 3–5) and dexamethasone (40 mg/body, days 3–5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma. In this study, a total of 32 patients with a median age of 64 years (range 38–79) who received an average of 2.6 cycles of R-IVAD from 2001 to 2009 in our institution were retrospectively analyzed. R-IVAD was given every 3 weeks up to a total of three courses with support by granulocyte colony stimulating factor. The overall response rate was 72%, with 56% complete response. On a median follow-up of 16 months (range 2–99), estimated 2-year overall survival (OS) and event-free survival were 55% and 36%, respectively. Of these patients, 10 successfully proceeded to consolidating high-dose chemotherapy followed by autologous stem cell transplantation, accounting for 90% of the 2-year OS. No treatment-related mortality was observed during the investigation. We, therefore, conclude that R-IVAD regimen is a safe and efficacious alternative for patients with relapsed or refractory aggressive B-cell lymphoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - toxicity</subject><subject>Biological and medical sciences</subject><subject>Cytarabine - administration & dosage</subject><subject>Dexamethasone - administration & dosage</subject><subject>Etoposide - administration & dosage</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Ifosfamide - administration & dosage</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, B-Cell - complications</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Lymphoma, B-Cell - mortality</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Salvage Therapy - adverse effects</subject><subject>Salvage Therapy - methods</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kduKFDEQhoMo7rj6AN5IEAQFozl0ks7luJ4WFgRRb5vqdDKTpU-bpNeZx_INzTije-VVKtRXVX_Vj9BTRt8wSvXbxDirJaGMEVrXFdndQytWK0mE1tV9tKKGSyI1o2foUUrXlDJNK_0QnXGmjFSUrtCv9Yid987mcOtwgv4WNg7n6CAPbsx4SWHc4OCn5GEInXuNXZ7mKf0J7T5DhDaMJe7cDgaXt5CmwxfGDseQl10YoMUvv5LLH-v3r7CfIp4hh9I64Z8hb3F0PczJdbhkovMRbJ7iHsNmE11KB1HviHV9j_v9MG-nAR6jBx765J6c3nP0_eOHbxefydWXT5cX6ytiKykyEUxYqVoOSrdeey4866wC4XUnTOs7yssJqkpI16pOczBcqVYp0xphfc2kOEfPj33nON0sLuXmelriWEY2tZaUG2NogdgRsnFKqehv5lg2jvuG0ebgUXP0qCkeNQePml2peXZqvLSD6_5V_DWlAC9OACQLfbnJaEO64yopqRKmcPzIpZIaNy7eKfz_9N-waqzK</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Miura, Katsuhiro</creator><creator>Takei, Kazuhiro</creator><creator>Kobayashi, Sumiko</creator><creator>Kiso, Satomi</creator><creator>Hirabayashi, Yukio</creator><creator>Hojo, Atsuko</creator><creator>Kodaira, Hitomi</creator><creator>Yagi, Mai</creator><creator>Kurita, Daisuke</creator><creator>Kobayashi, Yujin</creator><creator>Tanaka, Toshitake</creator><creator>Iriyama, Noriyoshi</creator><creator>Hatta, Yoshihiro</creator><creator>Kura, Yoshimasa</creator><creator>Yamazaki, Tetsuo</creator><creator>Sawada, Umihiko</creator><creator>Takeuchi, Jin</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20110701</creationdate><title>An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma</title><author>Miura, Katsuhiro ; Takei, Kazuhiro ; Kobayashi, Sumiko ; Kiso, Satomi ; Hirabayashi, Yukio ; Hojo, Atsuko ; Kodaira, Hitomi ; Yagi, Mai ; Kurita, Daisuke ; Kobayashi, Yujin ; Tanaka, Toshitake ; Iriyama, Noriyoshi ; Hatta, Yoshihiro ; Kura, Yoshimasa ; Yamazaki, Tetsuo ; Sawada, Umihiko ; Takeuchi, Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-313c56b2a67bf7f23f1dc6a3f7d39bfd026954435eb6d72a9266b669b93cf8153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - toxicity</topic><topic>Biological and medical sciences</topic><topic>Cytarabine - administration & dosage</topic><topic>Dexamethasone - administration & dosage</topic><topic>Etoposide - administration & dosage</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Ifosfamide - administration & dosage</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, B-Cell - complications</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Lymphoma, B-Cell - mortality</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Salvage Therapy - adverse effects</topic><topic>Salvage Therapy - methods</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miura, Katsuhiro</creatorcontrib><creatorcontrib>Takei, Kazuhiro</creatorcontrib><creatorcontrib>Kobayashi, Sumiko</creatorcontrib><creatorcontrib>Kiso, Satomi</creatorcontrib><creatorcontrib>Hirabayashi, Yukio</creatorcontrib><creatorcontrib>Hojo, Atsuko</creatorcontrib><creatorcontrib>Kodaira, Hitomi</creatorcontrib><creatorcontrib>Yagi, Mai</creatorcontrib><creatorcontrib>Kurita, Daisuke</creatorcontrib><creatorcontrib>Kobayashi, Yujin</creatorcontrib><creatorcontrib>Tanaka, Toshitake</creatorcontrib><creatorcontrib>Iriyama, Noriyoshi</creatorcontrib><creatorcontrib>Hatta, Yoshihiro</creatorcontrib><creatorcontrib>Kura, Yoshimasa</creatorcontrib><creatorcontrib>Yamazaki, Tetsuo</creatorcontrib><creatorcontrib>Sawada, Umihiko</creatorcontrib><creatorcontrib>Takeuchi, Jin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miura, Katsuhiro</au><au>Takei, Kazuhiro</au><au>Kobayashi, Sumiko</au><au>Kiso, Satomi</au><au>Hirabayashi, Yukio</au><au>Hojo, Atsuko</au><au>Kodaira, Hitomi</au><au>Yagi, Mai</au><au>Kurita, Daisuke</au><au>Kobayashi, Yujin</au><au>Tanaka, Toshitake</au><au>Iriyama, Noriyoshi</au><au>Hatta, Yoshihiro</au><au>Kura, Yoshimasa</au><au>Yamazaki, Tetsuo</au><au>Sawada, Umihiko</au><au>Takeuchi, Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>94</volume><issue>1</issue><spage>90</spage><epage>96</epage><pages>90-96</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m
2
, day 1), ifosfamide (1500 mg/m
2
on days 3–7), etoposide (150 mg/m
2
, days 3–5), cytarabine (100 mg/m
2
, days 3–5) and dexamethasone (40 mg/body, days 3–5) (R-IVAD) for relapsed or refractory aggressive B-cell lymphoma. In this study, a total of 32 patients with a median age of 64 years (range 38–79) who received an average of 2.6 cycles of R-IVAD from 2001 to 2009 in our institution were retrospectively analyzed. R-IVAD was given every 3 weeks up to a total of three courses with support by granulocyte colony stimulating factor. The overall response rate was 72%, with 56% complete response. On a median follow-up of 16 months (range 2–99), estimated 2-year overall survival (OS) and event-free survival were 55% and 36%, respectively. Of these patients, 10 successfully proceeded to consolidating high-dose chemotherapy followed by autologous stem cell transplantation, accounting for 90% of the 2-year OS. No treatment-related mortality was observed during the investigation. We, therefore, conclude that R-IVAD regimen is a safe and efficacious alternative for patients with relapsed or refractory aggressive B-cell lymphoma.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>21695600</pmid><doi>10.1007/s12185-011-0884-x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2011-07, Vol.94 (1), p.90-96 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_journals_875029990 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antineoplastic Combined Chemotherapy Protocols - toxicity Biological and medical sciences Cytarabine - administration & dosage Dexamethasone - administration & dosage Etoposide - administration & dosage Hematologic and hematopoietic diseases Hematology Humans Ifosfamide - administration & dosage Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell - complications Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - mortality Medical sciences Medicine Medicine & Public Health Middle Aged Oncology Original Article Retrospective Studies Rituximab Salvage Therapy - adverse effects Salvage Therapy - methods Survival Analysis Treatment Outcome |
| title | An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T03%3A42%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20effective%20salvage%20treatment%20using%20ifosfamide,%20etoposide,%20cytarabine,%20dexamethasone,%20and%20rituximab%20(R-IVAD)%20for%20patients%20with%20relapsed%20or%20refractory%20aggressive%20B-cell%20lymphoma&rft.jtitle=International%20journal%20of%20hematology&rft.au=Miura,%20Katsuhiro&rft.date=2011-07-01&rft.volume=94&rft.issue=1&rft.spage=90&rft.epage=96&rft.pages=90-96&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-011-0884-x&rft_dat=%3Cproquest_cross%3E2392485081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=875029990&rft_id=info:pmid/21695600&rfr_iscdi=true |